ClinicalTrials.gg
CompletedNCT03738215Updated Oct 25, 2022Results posted

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

A Phase 3 interventional study of Cariprazine and Placebo in Major Depressive Disorder, sponsored by AbbVie. Completed at 125 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-25.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
759
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Enrollment
8th of 53
759 · median 442
Started
2018
with 6 others
Phase 3
31 of 53
none open now
Registered
47th of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 8th largest by enrollment, is one of 7 that started in 2018, is one of 31 in phase 3, and was the 47th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written has been obtained.
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]).
  • Patient must be an outpatient at the time of Visit 1 (Screening).
  • Patient meets the criteria for MDD based on SCID-5, with a current major depressive episode of at least 8 weeks and not exceeding 24 months in duration at Visit 1/Screening. A diagnosis of MDD with psychotic features will be acceptable.
  • Diagnosis of MDD confirmed through a formal adjudication process.
  • Patient demonstrates ability to follow study instructions and likely to complete all required visits.
  • Patient must have an inadequate response, as measured by the modified ATRQ, to 1 to 3 antidepressants administered during the current episode at an adequate dose (as per package insert) and for at least 6 weeks duration, with at least one dose escalation during the current depressive episode.
  • Only one antidepressant (of sufficient dose per package insert and taken for at least 6 weeks) will be allowed at randomization and patients must agree to continue taking the same ADT dosing regimen through completion of Visit 6/ET. Patients who are taking more than one antidepressant at Screening, regardless of the indication, will need to discontinue all other antidepressants prior to Visit 2 (Baseline).
  • Male and female patients must agree to use a medically acceptable and highly effective method of during the course of the entire study.
  • Women of (only) must have a negative serum β-human chorionic gonadotropin pregnancy test prior to Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any current psychiatric diagnosis other than MDD (including those with current intellectual development disability) with the exception of specific phobias.
  • Patient has a history of intolerance or to cariprazine or other drugs of the same class or to rescue medications.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
759 participants (actual)

Study arms

  • Experimental
    Cariprazine 1.5 mg/Day + ADT

    During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).

    Drug: Cariprazine

  • Experimental
    Cariprazine 3 mg/Day + ADT

    During the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).

    Drug: Cariprazine

  • Placebo comparator
    Placebo + ADT

    During the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).

    Drug: Placebo

Interventions

  • Cariprazine supplied in capsules

  • DrugPlacebo

    Placebo supplied in capsules

06

What researchers measure

Primary outcomes

  1. Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)

    The MADRS is a 10-item, clinician-rated scale that evaluates the patient's depressive symptomatology during the past week. Patients are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score

    The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher scores indicate worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

    Time frame: Baseline and Week 6

07

Results

Posted Oct 25, 2022

Participant flow

Double-blind Treatment Period (6 Weeks)
Participant flow — Double-blind Treatment Period (6 Weeks)
MilestonePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Started253252252
Completed229231219
Not completed242133
Withdrew: Protocol violation010
Withdrew: Lack of efficacy220
Withdrew: Adverse event6318
Withdrew: Withdrawal by subject13119
Withdrew: Non-compliance with study drug011
Withdrew: Lost to follow-up335
Safety Follow Up Period (4 Weeks)
Participant flow — Safety Follow Up Period (4 Weeks)
MilestonePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Started240239238
Completed237234230
Not completed358
Withdrew: Adverse event001
Withdrew: Reason not specified020
Withdrew: Withdrawal by subject113
Withdrew: Lost to follow-up224

Outcome measures

PrimaryTotal Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)

The MADRS is a 10-item, clinician-rated scale that evaluates the patient's depressive symptomatology during the past week. Patients are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · score on a scale
Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)
score on a scalePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)-11.5 ± 0.70-14.1 ± 0.70-13.1 ± 0.70
Statistical analysis
  • Placebo + ADT vs Cariprazine 1.5 mg/Day + ADT · MMRM · p = 0.0050 (Adjusted P-Value (based on truncated Hochberg with parameter=0.9)) · Least squares mean difference: -2.5 · 95% CI -4.17 to -0.89MMRM = mixed-effects model for repeated measures
  • Placebo + ADT vs Cariprazine 3 mg/Day + ADT · MMRM · p = 0.0727 (Adjusted P-Value (based on truncated Hochberg with parameter=0.9)) · Least squares mean difference: -1.5 · 95% CI -3.16 to 0.12MMRM = mixed-effects model for repeated measures
SecondaryChange From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score

The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher scores indicate worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score
score on a scalePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score-1.1 ± 0.09-1.4 ± 0.09-1.3 ± 0.09
Statistical analysis
  • Placebo + ADT vs Cariprazine 1.5 mg/Day + ADT · MMRM · p = 0.0727 (Adjusted P-Value (based on Hochberg procedure)) · Lease squares mean difference: -0.3 · 95% CI -0.49 to -0.07MMRM = mixed-effects model for repeated measures
  • Placebo + ADT vs Cariprazine 3 mg/Day + ADT · MMRM · p = 0.0944 (Adjusted P-Value (based on Hochberg procedure)) · Least squares mean difference: -0.2 · 95% CI -0.39 to 0.03MMRM = mixed-effects model for repeated measures.

Adverse events

Collected over First Dose of study drug until 30 days after the last dose of study drug (up to 12 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + ADT0/253 (0%)2/253 (0.8%)39/253 (15.4%)
Cariprazine 1.5 mg/Day + ADT0/252 (0%)3/252 (1.2%)68/252 (27%)
Cariprazine 3 mg/Day + ADT0/252 (0%)3/252 (1.2%)62/252 (24.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
APPENDICITISInfections and infestations0/2530/2521/252
KIDNEY INFECTIONInfections and infestations0/2530/2521/252
FALLInjury, poisoning and procedural complications0/2531/2520/252
FIBULA FRACTUREInjury, poisoning and procedural complications0/2531/2520/252
TIBIA FRACTUREInjury, poisoning and procedural complications0/2531/2520/252
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions0/2531/2520/252
DEPRESSIONPsychiatric disorders1/2530/2521/252
SOCIAL STAY HOSPITALISATIONSocial circumstances0/2531/2520/252
MULTIPLE SCLEROSISNervous system disorders1/2530/2520/252
Most frequent other events
Most frequent other events
EventPlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
HEADACHENervous system disorders16/25324/25211/252
NAUSEAGastrointestinal disorders6/25320/25216/252
AKATHISIANervous system disorders3/25313/25220/252
INSOMNIAPsychiatric disorders11/25318/25216/252
SOMNOLENCENervous system disorders7/25313/25211/252

Baseline characteristics

Safety Population included all participants in the randomized population who took ≥ 1 dose of double-blind investigational product.

Age, Continuous
Age, Continuous(years)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Mean46.4 ± 11.8943.3 ± 13.5944.8 ± 13.3344.8 ± 13.00
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Female184191180555
Male696172202
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Hispanic or Latino25241968
Not Hispanic or Latino228228233689
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
American Indian or Alaska Native1102
Asian54716
Native Hawaiian or Other Pacific Islander1304
Black or African American433730110
White203205215623
More than one race0202
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
United States152153153458
Bulgaria353434103
Estonia1010929
Germany13121237
Hungary77721
Ukraine333334100
United Kingdom3339
08

Study locations

125 sites
  • Alea Research /ID# 234789
    Phoenix, Arizona 85012-2707, United States
  • Atria Clinical Research /ID# 237988
    Little Rock, Arkansas 72209-7040, United States
  • Woodland Research Northwest, LLC /ID# 236641
    Rogers, Arkansas 72758-6442, United States
  • California Pharmaceutical Research Institute /ID# 236732
    Anaheim, California 92804-3738, United States
  • Advanced Research Center /ID# 237957
    Anaheim, California 92805, United States
  • Axiom Research /ID# 236268
    Colton, California 92324, United States
  • ATP Clinical Research, Inc /ID# 236619
    Costa Mesa, California 92626-4607, United States
  • ProScience Research Group /ID# 236442
    Culver City, California 90230-6632, United States
  • Collaborative Neuroscience Research - Orange County /ID# 237639
    Garden Grove, California 92845, United States
  • Irvine Clinical Research /ID# 237409
    Irvine, California 92614, United States
  • Omega Clinical Trials LLC /ID# 238168
    La Habra, California 90631-3842, United States
  • Synergy San Diego /ID# 236654
    Lemon Grove, California 91945-2956, United States
  • Anderson Clinical Research /ID# 236627
    Redlands, California 92374-4555, United States
  • Sharp Mesa Vista Hospital /ID# 235797
    San Diego, California 92123, United States
  • Viking Clinical Research /ID# 236614
    Temecula, California 92591-6200, United States
  • Olympian Clinical Research /ID# 237417
    Clearwater, Florida 33756, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Reliable Clinical Research /ID# 234786
    Hialeah, Florida 33012-5830, United States
  • CNS Healthcare - Jacksonville /ID# 238241
    Jacksonville, Florida 32256-6039, United States
  • Space Coast Neuropsychiatric Research Institute /ID# 235765
    Palm Bay, Florida 32905, United States
  • University of South Florida /ID# 234386
    Tampa, Florida 33606, United States
  • Institute for Advanced Medical Research /ID# 236672
    Alpharetta, Georgia 30022-1142, United States
  • iResearch Atlanta, LLC /ID# 237389
    Decatur, Georgia 30030, United States
  • Psych Atlanta /ID# 235835
    Marietta, Georgia 30060, United States
  • Capstone Clinical Research /ID# 236546
    Libertyville, Illinois 60048-5341, United States
  • Pillar Clinical Research /ID# 235702
    Lincolnwood, Illinois 60712, United States
  • NeuroPsychiatric Research Practice & Associate LTD /ID# 234636
    Winfield, Illinois 60190, United States
  • Lake Charles Clinical Trials /ID# 237723
    Lake Charles, Louisiana 70629, United States
  • J. Gary Booker MD APMC /ID# 234514
    Shreveport, Louisiana 71104, United States
  • Pharmasite Research, Inc. /ID# 237395
    Baltimore, Maryland 21208, United States
  • CBH Health LLC /ID# 234536
    Gaithersburg, Maryland 20877, United States
  • Michigan Clinical Research Institute /ID# 234792
    Ann Arbor, Michigan 48105-3205, United States
  • NeuroBehavioral Medicine Group /ID# 236671
    Bloomfield Hills, Michigan 48302, United States
  • Precise Research Centers /ID# 236598
    Flowood, Mississippi 39232-8839, United States
  • Millennium Psychiatric Associates LLC /ID# 235989
    Saint Louis, Missouri 63132, United States
  • Alivation Research /ID# 236583
    Lincoln, Nebraska 68526-9474, United States
  • Altea Research Institute /ID# 236726
    Las Vegas, Nevada 89102-1955, United States
  • Hassman Research Institute /ID# 237501
    Berlin, New Jersey 08009, United States
  • Integrative Clinical Trials /ID# 236656
    Brooklyn, New York 11229-3576, United States
  • Manhattan Behavioral Medicine PLLC /ID# 236314
    New York, New York 10036, United States
  • Finger Lakes Clinical Research /ID# 236578
    Rochester, New York 14618-1609, United States
  • New Hope Clinical Research Inc. /ID# 234557
    Charlotte, North Carolina 28211, United States
  • Richard Weisler MD, PA & Assoc /ID# 237424
    Raleigh, North Carolina 27609, United States
  • Quest Therapeutics of Avon Lake /ID# 236282
    Avon Lake, Ohio 44012, United States
  • CTI Clinical Trial and Consulting /ID# 236271
    Cincinnati, Ohio 45212, United States
  • The Ohio State University Department of Psychiatry /ID# 234583
    Columbus, Ohio 43210, United States
  • CincyScience /ID# 236391
    West Chester, Ohio 45069, United States
  • IPS Research Company /ID# 237671
    Oklahoma City, Oklahoma 73106, United States
  • Sooner Clinical Research /ID# 236346
    Oklahoma City, Oklahoma 73112, United States
  • Oregon Center for Clinical Investigations, Inc. - Portland /ID# 236649
    Portland, Oregon 97214-2569, United States
  • Lehigh Center for Clinical Research /ID# 236702
    Allentown, Pennsylvania 18104-5034, United States
  • Coastal Carolina Research Center /ID# 235909
    North Charleston, South Carolina 29405, United States
  • Psychiatric Consultants PC /ID# 235839
    Franklin, Tennessee 37067, United States
  • Clinical Neuroscience Solutions - Memphis /ID# 237476
    Memphis, Tennessee 38119, United States
  • Austin Clinical Trial Partners /ID# 236551
    Austin, Texas 78737, United States
  • BioBehavioral Research of Austin /ID# 236477
    Austin, Texas 78759-5290, United States
  • Houston Clinical Trials /ID# 234442
    Bellaire, Texas 77401-2928, United States
  • FutureSearch Trials of Dallas, LP /ID# 236275
    Dallas, Texas 75231, United States
  • Earle Research /ID# 236661
    Friendswood, Texas 77546, United States
  • Red Oak Psychiatry Associates /ID# 236600
    Houston, Texas 77090-2641, United States
  • AIM Trials /ID# 236369
    Plano, Texas 75093, United States
  • Pillar Clinical Research LLC /ID# 234465
    Richardson, Texas 75080, United States
  • Neuropsychiatric Associates LLC/DBA Woodstock Research Center /ID# 236087
    Woodstock, Vermont 05091, United States
  • Northwest Clinical Research Center /ID# 237584
    Bellevue, Washington 98007, United States
  • Core Clinical Research /ID# 236405
    Everett, Washington 98201, United States
  • UMHAT Alexandrovska EAD /ID# 237834
    Sofiya, Sofia 1431, Bulgaria
  • State Psychiatry Hospital-Kardzhali; Third Male Department /ID# 234625
    Kardzhali, 6600, Bulgaria
  • MHAT Dr. Hristo Stambolski EOOD; Hospital Pharmacy /ID# 234773
    Kazanlak, 6100, Bulgaria
  • UMHAT Dr Georgi Stranski EAD /ID# 237828
    Pleven, 5800, Bulgaria
  • Medical Center Mentalcare OOD /ID# 234934
    Plovdiv, 4000, Bulgaria
  • Clinic of Psychiatry /ID# 235878
    Plovdiv, 4002, Bulgaria
  • Mental health Centre-Ruse EOOD /ID# 234775
    Ruse, 7003, Bulgaria
  • Medical Center Sveti Naum EOOD /ID# 236069
    Sofia, 1113, Bulgaria
  • Medical Center Hera EOOD /ID# 235859
    Sofia, 1510, Bulgaria
  • Medical complex Doverie /ID# 238307
    Sofia, 1632, Bulgaria
  • Medical Centre - VAS OOD /ID# 235719
    Targovishte, 7700, Bulgaria
  • Diagnostic consultative center Mladost M /ID# 236253
    Varna, 9020, Bulgaria
  • Diagnostic consultative center Mladost M /ID# 236254
    Varna, 9020, Bulgaria
  • Mental Health Center - Veliko Tarnovo EOOD Veliko Tarnovo /ID# 236078
    Veliko Tarnovo, 5000, Bulgaria
  • Mental Health Center - Vratsa EOOD Hospital Pharmacy /ID# 235960
    Vratsa, 3000, Bulgaria
  • Tartu University Hospital /ID# 237079
    Tartu Linn, Tartumaa 50406, Estonia
  • West Tallinn Central Hospital /ID# 237078
    Tallinn, 10617, Estonia
  • Marienthali Kliinik /ID# 235677
    Tallinn, 11315, Estonia
  • OU Jaanson and Laane /ID# 234985
    Tartu, 50406, Estonia
  • Universitaetsklinikum Frankfurt /ID# 237292
    Frankfurt am Main, Hessen 60590, Germany
  • Private Practice - Dr. Thomsen /ID# 235713
    Berlin, 10245, Germany
  • Emovis GmbH /ID# 235010
    Berlin, 10629, Germany
  • MVZ LIO Berlin /ID# 235711
    Berlin, 12209, Germany
  • BAG Prof. Dr. Kunte / Dr. sc. med. A. Schulze /ID# 235970
    Berlin, 13156, Germany
  • Arztpraxis Dr Kirsten Hahn /ID# 235958
    Berlin, 13187, Germany
  • Klinikum Chemnitz gGmbH /ID# 237758
    Chemnitz, 09116, Germany
  • Studienzentrum Nord-West /ID# 236357
    Westerstede, 26655, Germany
  • Bacs-Kiskun Megyei Oktatokorhaz Szent-Kereszt Korhaz /ID# 235974
    Kalocsa, Bacs-Kiskun 6300, Hungary
  • PsychoTech Kft. /ID# 235008
    Pecs, Baranya 7627, Hungary
  • Bugat Pal Korhaz /ID# 238145
    Gyöngyös, Heves 3200, Hungary
  • Szent Borbala Korhaz /ID# 238293
    Tatabanya, Komarom-Esztergom 2800, Hungary
  • Obudai Egeszsegugyi Centrum Kft. /ID# 237495
    Budapest, Pest 1036, Hungary
  • Clinexpert Kft /ID# 237266
    Budapest, 1033, Hungary
  • Jozsefvarosi Szent Kozma Egeszsegugyi Kozpont /ID# 235095
    Budapest, 1084, Hungary
  • Semmelweis Egyetem /ID# 237096
    Budapest, 1085, Hungary

Showing the first 100 of 125 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2021, 34 months.

Results were first posted in Oct 2022, 1 year after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 34 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2018
First posted
Nov 13, 2018
StartActual
Nov 9, 2018
Primary completionActual
Sep 30, 2021
CompletionActual
Sep 30, 2021
Results first posted
Oct 25, 2022
Last update
Oct 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03738215
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Nov 9, 2018
Primary completion
Sep 30, 2021
Completion
Sep 30, 2021
Results posted
Oct 25, 2022
Last update
Oct 25, 2022

Study contacts

Abbvie INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion